Raffles Medical's Shares Seen Attractively Priced as Pre-results Entry Point

Dow Jones

Jul 07

0814 GMT - Raffles Medical's shares appear attractively priced as an entry point ahead of its 1H results, says RHB Research's Shekhar Jaiswal in a note. Its 1H earnings are likely to be a crucial check-in for its China segment, as the Singapore healthcare company said it aims for at least one China hospital to achieve Ebitda break-even by end-2026, he says. Meanwhile, the company's insurance segment is likely to benefit from new regulations for a certain plan type in Singapore, which should structurally improve industry claims ratios in the city-state, he says. He reckons Raffles Medical shares trade at a discount to its Southeast Asian healthcare peers despite its strong earnings visibility. RHB retains its buy rating and 1.30 Singapore dollar target price on Raffles Medical, which rises 1.1% to S$0.93. (megan.cheah@wsj.com)

(END) Dow Jones Newswires

July 07, 2026 04:14 ET (08:14 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2649683600"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2649683600\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2649683600?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-07 16:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649683600","market":"us","top_or_hot":-1,"title":"Raffles Medical's Shares Seen Attractively Priced as Pre-results Entry Point","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0814 GMT - Raffles Medical's shares appear attractively priced as an entry point ahead of its 1H results, says RHB Research's Shekhar Jaiswal in a note. Its 1H earnings are likely to be a crucial check-in for its China segment, as the Singapore healthcare company said it aims for at least one China hospital to achieve Ebitda break-even by end-2026, he says. Meanwhile, the company's insurance segment is likely to benefit from new regulations for a certain plan type in Singapore, which should structurally improve industry claims ratios in the city-state, he says. He reckons Raffles Medical shares trade at a discount to its Southeast Asian healthcare peers despite its strong earnings visibility. RHB retains its buy rating and 1.30 Singapore dollar target price on Raffles Medical, which rises 1.1% to S$0.93. (megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 07, 2026 04:14 ET (08:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Raffles Medical's Shares Seen Attractively Priced as Pre-results Entry Point</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRaffles Medical's Shares Seen Attractively Priced as Pre-results Entry Point\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-07 16:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0814 GMT - Raffles Medical's shares appear attractively priced as an entry point ahead of its 1H results, says RHB Research's Shekhar Jaiswal in a note. Its 1H earnings are likely to be a crucial check-in for its China segment, as the Singapore healthcare company said it aims for at least one China hospital to achieve Ebitda break-even by end-2026, he says. Meanwhile, the company's insurance segment is likely to benefit from new regulations for a certain plan type in Singapore, which should structurally improve industry claims ratios in the city-state, he says. He reckons Raffles Medical shares trade at a discount to its Southeast Asian healthcare peers despite its strong earnings visibility. RHB retains its buy rating and 1.30 Singapore dollar target price on Raffles Medical, which rises 1.1% to S$0.93. (megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 07, 2026 04:14 ET (08:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK6092","symbol_name":"保健护理机构","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2649683600","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649683600","pubTimestamp":1783412040,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0814 GMT - Raffles Medical's shares appear attractively priced as an entry point ahead of its 1H results, says RHB Research's Shekhar Jaiswal in a note. Its 1H earnings are likely to be a crucial check-in for its China segment, as the Singapore healthcare company said it aims for at least one China hospital to achieve Ebitda break-even by end-2026, he says. Meanwhile, the company's insurance segment is likely to benefit from new regulations for a certain plan type in Singapore, which should structurally improve industry claims ratios in the city-state, he says. He reckons Raffles Medical shares trade at a discount to its Southeast Asian healthcare peers despite its strong earnings visibility. RHB retains its buy rating and 1.30 Singapore dollar target price on Raffles Medical, which rises 1.1% to S$0.93.  Dow Jones NewswiresJuly 07, 2026 04:14 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK6092":"保健护理机构","BK6511":"医疗保健服务概念","BSL.SI":"莱佛士医疗"},"translate_title":"莱佛士医疗(Raffles Medical)的股价被视为业绩前切入点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSL.SI":1.5},"content_text":"0814 GMT - Raffles Medical's shares appear attractively priced as an entry point ahead of its 1H results, says RHB Research's Shekhar Jaiswal in a note. Its 1H earnings are likely to be a crucial check-in for its China segment, as the Singapore healthcare company said it aims for at least one China hospital to achieve Ebitda break-even by end-2026, he says. Meanwhile, the company's insurance segment is likely to benefit from new regulations for a certain plan type in Singapore, which should structurally improve industry claims ratios in the city-state, he says. He reckons Raffles Medical shares trade at a discount to its Southeast Asian healthcare peers despite its strong earnings visibility. RHB retains its buy rating and 1.30 Singapore dollar target price on Raffles Medical, which rises 1.1% to S$0.93. (megan.cheah@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 07, 2026 04:14 ET (08:14 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}